Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

December 6, 2015 updated by: Dr. Victor H.F. Lee, The University of Hong Kong

Efficacy and Safety of Afatinib in Patients With EGFR-mutated Metastatic Non-small-cell Lung Cancer Previously Responsive to First-generation Tyrosine-kinase Inhibitors and Chemotherapy

The investigators prospectively evaluated in this study the efficacy and safety profiles of afatinib as 3rd or 4th line treatment after prior failure to systemic chemotherapy and first-generation EGFR-TKI under a Boehringer Ingelheim sponsored Compassionate Use Program (CUP), with comparison of our historical cohort who received erlotinib after previous failure to systemic chemotherapy and first-generation EGFR-TKI.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Study background The investigators prospectively evaluated the use of afatinib as 3rd or 4th line treatment after progression to one line of first-generation EGFR-TKI therapy and at least one line of systemic chemotherapy under this CUP. All patients had documented EGFR activating mutations before the start of afatinib. Determination of EGFR mutation analysis of all patients was described previously. Formalin-fixed paraffin-embedded tumor biopsies before starting 1st TKI therapy were retrieved. Briefly, tumor enrichment was performed by micro-dissection under light microscopy. Genomic DNA was extracted using QIAmp DNA FFPE Tissue kit (Qiagen, Hilden, Germany), followed by polymerase chain reaction (PCR) amplification of EGFR exons 18 to 21 using intron-based primers and sequenced in both forward and reverse directions.

Study population Patients who had EGFR-mutated metastatic NSCLC with prior documented objective response to first-generation TKI (gefitinib or erlotinib) for 6 months and prior treatment of at least 1 line of systemic chemotherapy were eligible to join the CUP offered by Boehringer-Ingelheim Pharma GmbH, Ingelheim, Germany. Patients who had received anti-vascular endothelial growth factor antagonist but not anti-EGFR monoclonal antibody in their previous courses of treatment, either alone or in combination with systemic chemotherapy were allowed to join this CUP. They all had baseline computed tomography scan of the brain, thorax and abdomen with at least 1 evaluable lesion and adequate serum hematological, hepatic and renal function as defined by LUX-Lung1 study.

Treatment The treating physicians then decided the starting dose of afatinib of either 50 mg, 40 mg or 30 mg once daily continuously. After commencement of afatinib, they had regular clinical follow up every 2 weeks for 4 weeks then every 4 weeks until permanent discontinuation of afatinib or death. They also had regular imaging with CT scan every 8-10 weeks for tumor response evaluation by Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1 [16]. Treatment interruption was needed for those who developed grade >= 3 adverse event until it was returned to grade 1 or less. Then afatinib could be resumed but at a one lower dose level. Those who received afatinib 30 mg daily as the initial starting dose would discontinue afatinib permanently if they developed grade >=3 events.

Assessment of efficacy and treatment-related toxicities All treatment-related toxicities were collected and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Objective response (OR) included complete response and partial response while disease control (DC) included complete response, partial response and stable disease according to RECIST 1.1. Survival outcomes included progression-free survival (PFS, defined as time from start of afatinib to first of date of objectively determined progressive disease or death from any cause) and overall survival (OS, time from start of afatinib to date of death from any cause). Time to progression (TTP) started from the date of afatinib commencement to the date of objectively determined progressive disease. All these parameters in those who received afatinib in this study were compared to a historical cohort of patients who received erlotinib after prior failure to gefitinib and at least one line of systemic chemotherapy. All patients in the historical cohort received erlotinib at 150 mg once daily, with the same treatment response evaluation, survival and toxicity assessment as for those who received afatinib.

Statistical analysis Mann-Whitney U was used for comparison of non-parametric variables and chi-square tests were performed for discrete variables. Kaplan-Meier methods with log-rank tests were employed for comparison of survival outcomes and Cox proportional hazard models were used for prognostic factors for PFS after afatinib or erlotinib in univariate and multivariate analyses, with afatinib versus erlotinib, age, sex, performance status, smoking status, histology, TTP for 1st TKI therapy, time interval between 1st TKI and afatinib or erlotinib, TTP for all lines of prior chemotherapy, time interval between last chemotherapy and afatinib or erlotinib as covariates. All statistical analyses were performed by Statistical Package for Social Sciences (SPSS) version 20.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • Department of Clinical Oncology, Queen Mary Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with stage IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who were previously responsive to one line of EGFR tyrosine kinase inhibitor and at least one line of systemic chemotherapy
  • Adequate hematological function (ANC >=1.5 x 10^9/l, Hb >=9.0 x 10^9/l, plt >=100 x 10^9/l)
  • Adequate renal function (with estimated creatinine clearance >=50ml/min as determined by Cockcroft-Gault formula)
  • Adequate liver function (ALT/AST <2.5 x upper normal limit or ALT/AST <5 x upper normal limit in the presence of liver metastasis)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
  • Evaluable target lesions according to RECIST 1.1 for tumour response assessment
  • Patients able to give written consent

Exclusion Criteria:

  • Symptomatic brain metastases requiring steroids/surgery/radiation therapy within 4 weeks of commencement of study medication
  • Significant cardiovascular abnormalities
  • Significant psychiatric disorders
  • Patients who have documented history of interstitial lung disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Afatinib
Afatinib 30 or 40 or 50mg daily orally after study recruitment until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
Drug: Afatinib
Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
Other Names:
  • Gilotrif
Drug: Erlotinib
Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
Other Names:
  • Tarceva
Experimental: Erlotinib
Erlotinib 150mg daily until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
Drug: Afatinib
Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
Other Names:
  • Gilotrif
Drug: Erlotinib
Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
Other Names:
  • Tarceva

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free survival
Time Frame: From date of start of study medication until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Time interval between date of start of afatinib or erlotinib to date of disease progression or death whichever comes earlier
From date of start of study medication until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate
Time Frame: Through study completion, an average of 12 months
Percentage of patients who derive objective response after drug treatment as judged by RECIST 1.1
Through study completion, an average of 12 months
Overall survival
Time Frame: From date of start of study medication until the date of death from any cause, assessed up to 100 months
Time interval between date of start of afatinib/erlotinib and date of death from any cause
From date of start of study medication until the date of death from any cause, assessed up to 100 months
Toxicity profiles
Time Frame: Through study completion, an average of 12 months
Adverse events or serious adverse events after afatinib/erlotinib
Through study completion, an average of 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The University of Hong Kong

Investigators

  • Principal Investigator: Victor Lee, MD, Department of Clinical Oncology, The University of Hong Kong

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Actual)

September 1, 2014

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

December 2, 2015

First Submitted That Met QC Criteria

December 6, 2015

First Posted (Estimate)

December 9, 2015

Study Record Updates

Last Update Posted (Estimate)

December 9, 2015

Last Update Submitted That Met QC Criteria

December 6, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Version 1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Clinical Trials on Afatinib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe